Arcellx, Inc.
ACLX
Classificação em ações
#2785
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Preço da ação
$115.07
Última sincronização: 2026-05-15
Valor de mercado
$6.73B
Variação (1 dia)
0.00%
Variação (1 ano)
32.61%
País
US
Negociar Arcellx, Inc. (ACLX)
Categoria
Healthcare
Lucros da Arcellx, Inc. (ACLX)
Lucros em Dec 2025 TTM: $-228.87M
De acordo com os últimos relatórios financeiros da Arcellx, Inc., os ganhos atuais da empresa são de $-228.87M. Em 2023, a empresa teve ganhos de $-70.03M, um aumento em relação a aos ganhos de 2022, que foram de $-188.68M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Arcellx, Inc. de 2018 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-228.87M | 117.39% |
| 2024 | $-105.28M | 50.34% |
| 2023 | $-70.03M | -62.89% |
| 2022 | $-188.68M | 190.41% |
| 2021 | $-64.97M | 102.43% |
| 2020 | $-32.10M | 78.58% |
| 2019 | $-17.97M | 116.32% |
| 2018 | $-8.31M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -2,404.81% |
US
|
|
| $-3.09B | 1,248.83% |
US
|
|
| $-4.02B | 1,654.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -952.31% |
NL
|
